NCT06673667View on ClinicalTrials.gov

First-in-human Study of Orally Administered KT-621 in Healthy Adult Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

118

Participants

Timeline

Start Date

October 22, 2024

Primary Completion Date

April 23, 2025

Study Completion Date

April 23, 2025

Conditions
Healthy Participants Study
Interventions
DRUG

KT-621

Oral drug

DRUG

Placebo

Oral drug

Trial Locations (2)

68502

Celerion, Lincoln

85283

Celerion, Phoenix

Sponsors
All Listed Sponsors
lead

Kymera Therapeutics, Inc.

INDUSTRY